A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

[1]  K. Flaherty,et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.

[2]  Yong Feng,et al.  LEF-1 Regulates Tyrosinase Gene Transcription In Vitro , 2015, PloS one.

[3]  B. Pruitt,et al.  Mechanical strain induces E-cadherin–dependent Yap1 and β-catenin activation to drive cell cycle entry , 2015, Science.

[4]  K. Brown,et al.  Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation , 2015, Cell reports.

[5]  E. Cuppen,et al.  Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib , 2015, Pigment cell & melanoma research.

[6]  U. Rothbauer,et al.  Monitoring Interactions and Dynamics of Endogenous Beta-catenin With Intracellular Nanobodies in Living Cells* , 2015, Molecular & Cellular Proteomics.

[7]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[8]  K. Flaherty,et al.  Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[10]  James T. Webber,et al.  Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. , 2014, Cell reports.

[11]  G. Long,et al.  Systemic treatment for BRAF-mutant melanoma: where do we go next? , 2014, The Lancet. Oncology.

[12]  A. Eggermont,et al.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies , 2014, Nature.

[13]  R. Moon,et al.  WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. , 2014, The Journal of clinical investigation.

[14]  P. Rothberg,et al.  ERBB3 is required for metastasis formation of melanoma cells , 2014, Oncogenesis.

[15]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[16]  Richard F. Kefford,et al.  Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling , 2014, PloS one.

[17]  P. Gimotty,et al.  MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines , 2014, Oncogene.

[18]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[19]  C. Weber,et al.  β-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. , 2014, Cellular signalling.

[20]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[21]  Amit Sharma,et al.  DNASU plasmid and PSI:Biology-Materials repositories: resources to accelerate biological research , 2013, Nucleic Acids Res..

[22]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[23]  G. Pupo,et al.  Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma , 2013, Molecular Cancer Therapeutics.

[24]  Jason B. Lee,et al.  Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. , 2013, The Journal of clinical investigation.

[25]  A. Chenn,et al.  AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development , 2013, Neural Development.

[26]  Dean Y. Li,et al.  The Small GTPase ARF6 Stimulates β-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis , 2013, Science Signaling.

[27]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[28]  Wenyi Wei,et al.  Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas , 2013, The Journal of investigative dermatology.

[29]  R. Moon,et al.  Regulating the response to targeted MEK inhibition in melanoma , 2012, Cell cycle.

[30]  R. Nusse,et al.  Wnt5a can both activate and repress Wnt/β-catenin signaling during mouse embryonic development. , 2012, Developmental biology.

[31]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[32]  S. Vetter,et al.  The nuclear factor κB inhibitor (E)-2-fluoro-4′-methoxystilbene inhibits firefly luciferase , 2012, Bioscience reports.

[33]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[34]  C. Nishigori,et al.  Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. , 2012, The Journal of investigative dermatology.

[35]  A. Hauschild,et al.  Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . , 2012 .

[36]  T. Golub,et al.  Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion , 2012, Nature.

[37]  G. Fuller,et al.  The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival , 2012, Oncotarget.

[38]  P. Sorger,et al.  A Dual Array-Based Approach to Assess the Abundance and Posttranslational Modification State of Signaling Proteins , 2012, Science Signaling.

[39]  R. Moon,et al.  Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma , 2012, Science Signaling.

[40]  Rachel Purcell,et al.  HGF/c-Met related activation of β-catenin in hepatoblastoma , 2011, Journal of experimental & clinical cancer research : CR.

[41]  T. Beißbarth,et al.  Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. , 2011, Carcinogenesis.

[42]  X. Dai,et al.  A WNTer Revisit: New Faces of β-Catenin and TCFs in Pluripotency , 2011, Science Signaling.

[43]  C. Garbe,et al.  β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance , 2011, PloS one.

[44]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Weeraratna,et al.  Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching , 2011, Pigment cell & melanoma research.

[46]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[47]  Shuanhu Zhou.  TGF‐β regulates β‐catenin signaling and osteoblast differentiation in human mesenchymal stem cells , 2011, Journal of cellular biochemistry.

[48]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[50]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[51]  Y. Rustum,et al.  Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers , 2010, Molecular Cancer.

[52]  S. Kaesler,et al.  Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. , 2010, Cancer research.

[53]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[54]  K. Aldape,et al.  EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. , 2009, Molecular cell.

[55]  S. Hladky,et al.  Decreased expression of multidrug efflux transporters in the brains of GSK-3β transgenic mice , 2009, Brain Research.

[56]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[57]  M. Bittner,et al.  The Wnt5A/Protein Kinase C Pathway Mediates Motility in Melanoma Cells via the Inhibition of Metastasis Suppressors and Initiation of an Epithelial to Mesenchymal Transition* , 2007, Journal of Biological Chemistry.

[58]  D. Jukic,et al.  Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.

[59]  R. Moon.  Faculty Opinions recommendation of Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. , 2006 .

[60]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[61]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[63]  E. Price,et al.  β-Catenin–induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor , 2002, The Journal of Cell Biology.

[64]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[65]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[66]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation , 2001, Oncogene.

[67]  A. Penzo-Méndez,et al.  The C‐terminal cytoplasmic Lys‐Thr‐X‐X‐X‐Trp motif in frizzled receptors mediates Wnt/β‐catenin signalling , 2000, The EMBO journal.

[68]  D. Raible,et al.  Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. , 2000, Genes & development.

[69]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[70]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[71]  P. Chapman.  Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[72]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. , 2001, Oncogene.